How a CRO Reduced Monitoring Costs by 50%+ in a Global Phase IV Oncology Study

CASE STUDY

A global oncology study was heading toward a $40 million monitoring strategy built on traditional, resource heavy oversight. 

But instead of following the expected path, the CRO challenged the status quo. By rethinking how risk, data, and site oversight were managed, they uncovered a more efficient way forward, one that reshaped the monitoring model without sacrificing quality or patient safety.

The impact? Significant cost reductions, smarter oversight, and a more modern approach to quality management in late phase trials.

Download the full case study to discover what changed, why it worked, and how this strategy can be applied to your own studies.